- Report
- February 2025
- 227 Pages
Global
From €2907EUR$3,240USD£2,552GBP
€3634EUR$4,050USD£3,190GBP
- Report
- August 2025
- 185 Pages
Global
From €3181EUR$3,545USD£2,792GBP
€3535EUR$3,939USD£3,102GBP
- Report
- August 2025
- 197 Pages
Global
From €3181EUR$3,545USD£2,792GBP
€3535EUR$3,939USD£3,102GBP
- Report
- August 2025
- 188 Pages
Global
From €3181EUR$3,545USD£2,792GBP
€3535EUR$3,939USD£3,102GBP
- Report
- November 2025
- 2285 Pages
Global
From €1120EUR$1,292USD£950GBP
- Report
- October 2025
- 250 Pages
Global
From €4029EUR$4,490USD£3,536GBP
- Report
- September 2025
- 250 Pages
Global
From €4029EUR$4,490USD£3,536GBP
- Report
- September 2025
- 250 Pages
Global
From €4029EUR$4,490USD£3,536GBP
- Report
- September 2025
- 250 Pages
Global
From €4029EUR$4,490USD£3,536GBP
- Report
- April 2025
- 250 Pages
Global
From €4029EUR$4,490USD£3,536GBP
- Report
- March 2025
- 175 Pages
Global
From €4029EUR$4,490USD£3,536GBP
- Report
- July 2025
- 181 Pages
Global
From €4038EUR$4,500USD£3,544GBP
- Report
- February 2025
- 185 Pages
Global
From €4038EUR$4,500USD£3,544GBP
- Training
- March 2026
- 2 Days
Global
€1532EUR$1,767USD£1,299GBP
€1768EUR$2,039USD£1,499GBP
- Report
- May 2025
- 102 Pages
Global
From €2647EUR$2,950USD£2,323GBP
- Report
- May 2025
- 799 Pages
Global
From €4306EUR$4,799USD£3,779GBP
- Report
- September 2025
- 455 Pages
Global
From €4306EUR$4,799USD£3,779GBP
- Report
- September 2025
- 393 Pages
Global
From €5130EUR$5,917USD£4,350GBP
- Report
- September 2025
- 1316 Pages
Global
From €1769EUR$2,040USD£1,500GBP
- Report
- September 2025
- 380 Pages
Global
From €4442EUR$4,950USD£3,898GBP

The Biosimilar market is a subset of the biotechnology industry that focuses on the development and production of biologic drugs that are similar to existing biologic drugs. Biosimilars are created using a process called recombinant DNA technology, which involves the manipulation of genetic material to create a drug that is similar to an existing biologic drug. Biosimilars are typically used to treat chronic conditions such as cancer, rheumatoid arthritis, and multiple sclerosis. Biosimilars are typically cheaper than their brand-name counterparts, making them an attractive option for patients and healthcare providers.
Some companies in the Biosimilar market include Amgen, Biocon, Celltrion, Dr. Reddy's Laboratories, Mylan, Pfizer, Sandoz, and Teva Pharmaceuticals. Show Less Read more